论文部分内容阅读
目的:探析胸腺肽联合化疗对非小细胞肺癌的治疗效果。方法:选取该院2013年1月至2015年12月收治的46例非小细胞肺癌患者,均通过病理学诊断得到确诊,将其随机分为观察组和对照组,各23例,观察组采取胸腺肽联合化疗,对照组采取单独化疗,比较两组治疗效果及毒副作用。结果:观察组Karnofsky体力状况评分上升率56.52%与对照组30.43%比较差异明显(P<0.05);治疗前两组各个指标差异(P>0.05),治疗后观察组CD4、NK细胞活性与治疗前比较显著上升(P<0.05),对照组NK细胞活性与治疗前比较显著下降(P<0.05)。两组均无严重毒副作用,主要是胃肠道反应及血液毒性反应。结论:胸腺肽联合化疗对非小细胞肺癌的治疗效果明显,明显提高患者的免疫力,改善患者生活质量,值得应用。
Objective: To investigate the therapeutic effect of thymosin combined with chemotherapy on non-small cell lung cancer. Methods: Forty-six patients with non-small cell lung cancer admitted to our hospital from January 2013 to December 2015 were diagnosed by pathological diagnosis. They were randomly divided into observation group and control group, with 23 cases in each group. The observation group adopted Thymosin combined with chemotherapy, the control group to take chemotherapy alone, the two groups were compared the therapeutic effect and side effects. Results: The Karnofsky physical condition score increased 56.52% in the observation group compared with 30.43% in the control group (P <0.05), and there was no significant difference between the two groups before treatment (P> 0.05) (P <0.05). The NK cell activity in the control group decreased significantly compared with that before treatment (P <0.05). No serious side effects were observed in both groups, mainly gastrointestinal reactions and hematologic toxicity. Conclusion: Thymosin combined with chemotherapy is effective in the treatment of non-small cell lung cancer, which obviously improves the immunity of patients and improves the quality of life of patients.